Cizzle Biotechnology Holdings PLC Final results for the year ended 31 December 2023
30 Avril 2024 - 10:12AM
RNS Regulatory News
RNS Number : 5816M
Cizzle Biotechnology Holdings PLC
30 April 2024
30 April 2024
Cizzle Biotechnology Holdings
plc
("Cizzle", "Cizzle Biotechnology", or the
"Company")
Final results for the year
ended 31 December 2023
Cizzle Biotechnology, the UK based
diagnostics developer, announces the
publication of the Company's Annual Report and Financial Statements
for the year ended 31 December 2023.
The Annual Financial Report is
available via http://www.rns-pdf.londonstockexchange.com/rns/5816M_1-2024-4-30.pdf and
will shortly be available to view on the Company's website
at: https://cizzlebiotechnology.com
Enquiries:
|
Cizzle Biotechnology Holdings plc
|
Via IFC Advisory
|
|
Allan Syms (Executive
Chairman)
|
|
|
Allenby Capital Limited - Joint Broker and Financial
Adviser
|
+44(0) 20 3328 5656
|
|
John Depasquale
|
|
|
George Payne
|
|
|
|
|
|
Novum Securities Limited - Joint Broker
|
+44(0) 20 7399 9400
|
|
Colin Rowbury
Jon Bellis
|
|
|
IFC
Advisory Limited - Financial Public Relations
|
+44(0) 20 3934 6630
|
|
Tim Metcalfe
|
|
|
Florence Chandler
|
|
About Cizzle Biotechnology
Cizzle is developing a blood test
for the early detection of lung cancer. The Company is a spin- out
from the University of York, founded in 2006, around the work of
Professor Coverley and colleagues. Its proof-of-concept prototype
test is based on the ability to detect a stable plasma biomarker, a
variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell
nuclear protein involved in DNA replication, and the targeted CIZ1B
variant is highly correlated with early-stage lung cancer. For more
information, please see https://cizzlebiotechnology.com
You can also follow the Company
through its twitter account @CizzlePlc and on LinkedIn
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DOCEAPLEDENLEEA
Cizzle Biotechnology (LSE:CIZ)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Cizzle Biotechnology (LSE:CIZ)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
